-
Another BlockBuster in HKEX18A Biotech Companies: IPO of DualityBio in Hong Kong, Introducing New Capital Engine in the ADC Field?
Kevin
April 15, 2025
On April 15, DualityBio, a rising star in the ADC field, was officially listed on the HKEX, marking one of the most high-profile IPOs in recent years in Chapter 18A Biotech Companies.
-
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion
Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
-
MSD, BI and CStone Pharmaceuticals Made Significant Investments in ROR1 ADC
Far-away from the Crowd
May 06, 2024
Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.
-
2024 Medical Breakthroughs: New Hope to Patients
Shruti Talashi
April 11, 2024
The pharmaceutical industry is set for a major shake-up in 2024.
-
Advancements in scientific technologies to Drug discovery and Development 2023
Shruti Talashi
January 02, 2024
Technological advancement apart from a deeper comprehension of disease biology, and an emphasis on breaking down conventional boundaries is driving this era of profound change in the drug development industry.
-
A comprehensive review of the currently marketed ADC drugs: the industry maintains high prosperity
WND
November 07, 2023
Antibody-drug conjugates (ADCs) are a class of drugs composed of antibodies targeting tumor antigens and a variable number of small molecule toxins linked through connectors.
-
PD-1 Inhibitor Combined with ADC, the Strong Cooperation of Innovent and Remegen
Far-away from the Crowd/PharmaSources
July 25, 2023
Recently, Innovent and Remegen will carry out a clinical research cooperation on the combination of Sintilimab Injection, a PD-1 inhibitor, with RC88, a novel antibody-drug conjugate targeting MSLN, and RC108, a novel ADC targeting c-MET, res.
-
More ADCs made in China, Led by Kelun Pharmaceutical, Expanding into the World Market with a Total Transaction Amount of over USD 20 billion
Yi/PharmaSources
June 06, 2023
More ADCs made in China, led by Kelun Pharmaceutical, expanding into the world market with a total transaction amount of over USD 20 billion.
-
Competitive Landscape of the New Drug Target Nectin-4 in China
Yefenghong/PharmaSources
May 22, 2023
Araris Biotech AG announced on April 17 that it will acquire ARS Pharmaceutical's Nectin-4 antibody. Araris Biotech intends to use the acquired Nectin-4 antibody to develop differentiated Nectin-4 ADCs using its proprietary linker technology.
-
The Increasing ADC+CDMO Industry Collaboration
Yefenghong/PharmaSources
April 19, 2023
Recently, the heat on ADC pipeline deals is around, and the deal sizes are kept refreshing.